PT - JOURNAL ARTICLE AU - Alay, Ania AU - Cordero, David AU - Hijazo-Pechero, Sara AU - Aliagas, Elisabet AU - Lopez-Doriga, Adriana AU - Marín, Raúl AU - Palmero, Ramón AU - Llatjós, Roger AU - Escobar, Ignacio AU - Ramos, Ricard AU - Padrones, Susana AU - Moreno, Víctor AU - Nadal, Ernest AU - Solé, Xavier TI - Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification AID - 10.1101/2020.08.14.20174789 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.14.20174789 4099 - http://medrxiv.org/content/early/2020/08/15/2020.08.14.20174789.short 4100 - http://medrxiv.org/content/early/2020/08/15/2020.08.14.20174789.full AB - Background Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasia affecting the lung mesothelium. Immune checkpoint inhibitors (ICI) in MPM have not been extremely successful, likely due to poor identification of suitable candidate patients for the therapy. We aimed to identify cellular immune fractions associated with clinical outcome and classify MPM patients based on their immune contexture. For each defined group, we sought for molecular specificities that could help further define our MPM classification at the genomic and transcriptomic level, as well as identify differential therapeutic strategies based on transcriptional signatures predictive of drug response.Methods The abundance of 20 immune cell fractions in 516 MPM samples from 7 gene expression datasets was inferred using Gene Set Variation Analysis. Identification of clinically relevant fractions was performed with Cox Proportional-Hazards Models adjusted for age, stage, sex, and tumor histology. Immune-based groups were identified using unsupervised classification.Results T-Helper 2 (TH2) and cytotoxic T (TC) cells were found to be consistently associated with overall survival. Three immune clusters (IG) were subsequently defined based on TH2 and TC immune infiltration levels: IG1 (54.5%) was characterized by high TH2 and low TC levels, IG2 (37%) had either low or high levels of both fractions, and IG3 (8.5%) was defined by low TH2 and high TC levels. IG1 and IG3 groups were associated with worse and better overall survival, respectively. The three groups showed differential molecular profiles, with IG1 enriched for CDKN2A and IFN-related genes deletions. At the transcriptional level, IG1 samples showed upregulation of proliferation signatures, while IG3 samples presented upregulation of immune and inflammation-related pathways. Finally, the integration of gene expression with functional signatures of drug response showed that IG3 patients might be more likely to respond to ICI, while IG1 patients could be more sensitive to PARP inhibitors.Conclusions This study identifies a novel immune-based signature with potential clinical relevance based on TH2 and TC levels, unveiling a fraction of MPM patients with better prognosis and who might benefit from immune-based therapies. Genomic and transcriptomic specificities of the different groups could be used to tailor potential therapies in the future.Competing Interest StatementVM is consultant to Bioiberica S.A.U. and Grupo Ferrer S.A., received research funds from Universal DX, and is coinvestigator in grants with Aniling. EN participated in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, Lilly, Roche, Pfizer, Takeda, Boehringer Ingelheim, Amgen and AstraZeneca. The other authors have no conflicts of interest to declare.Funding StatementThis work is supported by the Carlos III National Health Institute funded by FEDER funds - a way to build Europe - [PI14/01109; PI18/00920]; the Government of Catalonia [2017SGR448]. XS is supported by RTI2018-102134-A-I00 grant funded by Spanish Ministry of Science and Innovation. EN received support from the SLT006/17/00127 grant, funded by the Department of Health of the Generalitat de Catalunya by the call “Acció instrumental d’intensificació de professionals de la salut”. This study has been funded by Sociedad Española de Oncología Médica (SEOM) through “Proyectos de Investigación para Grupo Emergente”.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study are available in public, open access repositories.